Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Tacchetti

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Pharmaceuticals (Basel, Switzerland)|December 16, 2020
The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple MyelomaE Zamagni, P Tacchetti, P Deias, et al.
Expert Review of Hematology|July 14, 2016
Multiple myeloma: disease response assessmentE Zamagni, P Tacchetti, C Terragna, et al.
Seminars in Oncology|October 19, 2013
Role of consolidation therapy in transplant eligible multiple myeloma patientsMichele Cavo, Annamaria Brioli, P Tacchetti, et al.
Expert Review of Hematology|December 5, 2015
Current and emerging triplet combination therapies for relapsed and refractory multiple myelomaL Pantani, A Brioli, P Tacchetti, et al.
Bone Marrow Transplantation|January 11, 2012
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition diseaseA Brioli, E Zamagni, S Pasquali, et al.
Neurology|August 8, 2007
Neuropathy in multiple myeloma treated with thalidomide: a prospective studyR Plasmati, F Pastorelli, M Cavo, et al.
Journal of Cancer Research and Clinical Oncology|October 9, 2025
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?M Talarico, S Barbato, V Maisnar, et al.
Mediterranean Journal of Hematology and Infectious Diseases|May 16, 2025
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and SequencingM Puppi, I Sacchetti, K Mancuso, et al.
Leukemia|October 8, 2015
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myelomaM Cavo, L Pantani, A Pezzi, et al.
Journal of Bone Oncology|March 24, 2025
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myelomaM Talarico, S Barbato, A Cattabriga, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Pharmaceuticals (Basel, Switzerland)|December 16, 2020
The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple MyelomaE Zamagni, P Tacchetti, P Deias, et al.
Expert Review of Hematology|July 14, 2016
Multiple myeloma: disease response assessmentE Zamagni, P Tacchetti, C Terragna, et al.
Seminars in Oncology|October 19, 2013
Role of consolidation therapy in transplant eligible multiple myeloma patientsMichele Cavo, Annamaria Brioli, P Tacchetti, et al.
Expert Review of Hematology|December 5, 2015
Current and emerging triplet combination therapies for relapsed and refractory multiple myelomaL Pantani, A Brioli, P Tacchetti, et al.
Bone Marrow Transplantation|January 11, 2012
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition diseaseA Brioli, E Zamagni, S Pasquali, et al.
Neurology|August 8, 2007
Neuropathy in multiple myeloma treated with thalidomide: a prospective studyR Plasmati, F Pastorelli, M Cavo, et al.
Journal of Cancer Research and Clinical Oncology|October 9, 2025
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?M Talarico, S Barbato, V Maisnar, et al.
Mediterranean Journal of Hematology and Infectious Diseases|May 16, 2025
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and SequencingM Puppi, I Sacchetti, K Mancuso, et al.
Leukemia|October 8, 2015
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myelomaM Cavo, L Pantani, A Pezzi, et al.
Journal of Bone Oncology|March 24, 2025
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myelomaM Talarico, S Barbato, A Cattabriga, et al.
Pageof 2